Barinthus Biotherapeutics
Barinthus is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutic candidates.
Barinthus is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutic candidates.
Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing innovative T-cell immunotherapeutic candidates to combat chronic infectious diseases, autoimmunity, and cancer. With a diverse pipeline centered around four proprietary platform technologies - ChAdOx, MVA, SNAP-TI, and SNAP-CI, the company is advancing a portfolio of five product candidates targeting various therapeutic areas.
Founded in 2016 and headquartered in the United Kingdom, Barinthus Biotherapeutics has garnered significant attention, with its latest Series B investment of $168.00M on 17 March 2021. The investment was led by esteemed backers including Future Planet Capital, Gilead Sciences, M&G Investments, Monaco Constitutional Reserve Fund, Oxford Science Enterprises, and Tencent.
The company's dedication to addressing critical medical needs through scientific expertise and a comprehensive portfolio positions it uniquely in the biotechnology, health, and pharmaceutical industries. Barinthus Biotherapeutics is committed to making a tangible difference in the lives of individuals affected by infectious diseases, autoimmunity, and cancer, illustrating a promising trajectory in the competitive biopharmaceutical landscape.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $168.00M | 6 |
|
17 Mar 2021 |
| Convertible Note | Unknown | 1 |
|
01 Nov 2020 |
| Series A | £6.00M | 2 |
|
20 Dec 2018 |
| Series A | £20.00M | 1 |
|
15 Jan 2018 |
| Seed Round | £10.00M | - | 08 Nov 2016 |
We care about your data, and we'd love to use cookies make your experience better.
